This article is sponsored content brought to you by Elanco.
Osteoarthritis (OA) is a debilitating condition that is surprisingly prevalent in young dogs. A recent study1 showed that almost 40% of dogs younger than 4 years of age had radiographic signs of OA. More importantly, almost 60% of these young dogs had pain associated with their condition. Clearly, many young dogs are suffering from OA without a formal diagnosis.
Early detection & timely pain control is crucial
A delay in diagnosing & treating OA can result in a number of deleterious effects, eventually leading to CNS sensitisation. Central sensitisation results in hyperalgesia, and in more severe cases, allodynia. Starting the discussion about canine OA early can significantly improve the quality of life of both dogs and their owners.
Utilising a collaborative approach involving various clinic personnel can allow pet owners to play an integral role in proactively monitoring their dogs for OA, especially for breeds that are at increased risk. Tools to help both vets and owners diagnose OA as early as possible can be found by visiting myelanco.com/au and using the search function to find: LOAD questionnaire and The Canine Osteo Arthritis Staging Tool (COAST).
Proper management requires a multimodal approach involving adequate pain relief, body weight optimisation, physiotherapy etc. Relieving OA pain & inflammation early can help restore mobility which in turn improves muscle mass and strength. Early intervention with a safe and effective drug is required to slow the vicious cycle of progressive deterioration in OA.
Galliprant™ – a revolution in the treatment of canine OA pain & inflammation
Unlike traditional NSAIDs, Galliprant allows the production of prostaglandins involved in gastrointestinal and renal homeostasis. To learn more about Galliprant’s novel mode of action, go to myElanco and watch the video: Galliprant™ mode of action.
Galliprant delivers the following benefits:
• Safe and effective in dogs with naturally occurring OA
• Convenient once daily treatment (for long term treatment appropriate monitoring is required)
• Well tolerated over 9 months at doses up to 10x the max. therapeutic daily dose
– All dogs completed the study
– No evidence of GI ulceration
– No kidney or liver problems
While osteoarthritis is often associated with old age, this is often not the case in dogs. Canine OA affects many young dogs and these dogs benefit greatly from adequate analgesia that is administered appropriately. Galliprant™ is very effective at treating the pain and inflammation associated with canine osteoarthritis, and it has become my NSAID of choice for the long-term treatment of canine OA. It is important to note that a multimodal approach is required to achieve the best outcome. Using Galliprant together with nutraceuticals and a tailored dietary and exercise regimen is key in achieving a successful outcome.”
Dr. Simon T. Kudnig BVSc, MVS, MS, FACVSc, Dip.ACVS
Specialist in Small Animal Surgery
ACVS Founding Fellow of Surgical Oncology.
Keen to learn more? Go to myElanco and complete the “Early Canine OA Detection and Management” course.
References:
1. Enomoto M et al. Prevalence of radiographic appendicular osteoarthritis and associated clinical signs in young dogs. Scientific Reports. 2024; 14(1): 2827.
Read product leaflet for full instructions.
The following mild and generally transient adverse reactions have been observed in dogs treated with grapiprant: vomiting, diarrhoea, inappetence and lethargy.
©2024 Elanco or its affiliates. Galliprant™, Elanco and diagonal bar logo are trademarks of Elanco or its affiliates. PM-AU-24-0512.
